Ovarian Cancer Action | June 2018 |Promising new ovarian cancer treatment could soon be available on the NHS
The National Institute for Health and Care Excellence (NICE) has issued draft guidance on a promising new ovarian cancer drug, niraparib, advising that it is a suitable candidate for use in the Cancer Drugs Fund (CDF) (Ovarian Cancer Action).
Ovarian cancer is the fifth most common cause of cancer death in women and has the highest mortality rate of all gynaecological cancers. Five-year survival in England and Wales is also among the lowest in Europe – well below the European average. While these figures are bleak, it is exciting to think that niraparib could provide a much-needed new option for many women with the disease.
“We are pleased that the NICE committee has recognised the high unmet need in ovarian cancer treatment,” said Katherine Taylor, Chief Executive of Ovarian Cancer Action. “Every day matters for patients and their families and we hope that the CDF submission is successful and will deliver access to many women in England and Wales as soon as possible. We also look forward to a review by the Scottish Medicines Consortium (SMC) later this year.”
Source: Ovarian Cancer Action
In the media: